Biocept (NASDAQ:BIOC) stock observed trading -83.11% off 52-week high price. On the other end, the stock has been noted 68.75% away from low price over the last 52-weeks. The stock disclosed a move of 6.38% away from 50 day moving average and -43.22% away from 200 day moving average. Moving closer, we can see that shares have been trading 25.81% off 20-day moving average. It has market cap of $36.65M.
On April 9, 2020, Biocept (NASDAQ:BIOC) a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, declared that it has verified a COVID-19 molecular diagnostic test, and plans to begin accepting physician-ordered testing requests for processing beginning on April 15, 2020.
Biocept has partnered with a national clinician network to accept patient samples and may obtain additional agreements as test capacity is increased. Biocept operates a high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego, with specialized, licensed molecular lab staff that have been trained in performing the COVID-19 testing. The lab will be using the FDA-approved for EUA (Emergency Use Authorization) testing ThermoFisher Scientific’s TaqPath™ molecular diagnostic platform and kit for SARS-CoV-2 (COVID-19).
While we continue to focus primarily on providing actionable results for patients diagnosed with cancer, we are pleased to support our clients and public health efforts by expanding our offerings to include COVID-19 testing. I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer, said Mike Nall, Biocept’s Chief Executive Officer. We will provide this critical testing to physicians as we fight the global coronavirus pandemic.
The USA based company Biocept moved with change of 25.05% to $0.36 with the total traded volume of 44341498 shares in recent session versus to an average volume of 12.79M. The stock was observed in the 5 days activity at 33.48%. The one month performance of stock was -5.44%. BIOC’s shares are at 7.71% for the quarter and driving a -66.69% return over the course of the past year and is now at 24.62% since this point in 2018. Right now the stock beta is 0.05. The average volatility for the week and month was at 13.61% and 17.48% respectively. There are 102.84M shares outstanding and 102.84M shares are floated in market.